Who's who

3 Houston innovators to know this week

Here's who you need to know this week in Houston innovation. Courtesy photos

This group of innovators to know this week are passionate people. From starting companies to making acquisitions, here's what they are up to and why you need to know their names.

Kelly McCormick, director of RED Labs

Photo courtesy of UH

Kelly McCormick is in the business of making University of Houston's entrepreneurs' dreams into realities. The RED Labs director wrote a guest article for InnovationMap about side hustles — what they are and how to make them worth their while.

"A side hustle has a science to it, and more importantly, it has an art," she writes. Read her full article here.

Randa Duncan Williams, chairman of Enterprise Products Partners LP

Photo courtesy of Texas Monthly

For the second time in three years, Texas Monthly has a new owner. But if Randa Duncan Williams — energy exec and heiress worth over $6 billion — has anything to say about it, she'll be the last new owner of the magazine. Duncan Williams — who acquired the magazine by way of a privately held company, Enterprise Products Company, that's a subsidiary of Enterprise Products Partners, the company her late father founded — says she wants to own the magazine "forever." Read the full story here.

Cody Gremminger, system engineer at Cyber One Solutions

Cody Gremminger

Photo courtesy of Cyber One Solutions

Cody Gremminger is running a booming tech services business with his fiance, Brian Carrico. The company is called Cyber One Solutions and provides management, service and IT support services to the greater Houston area with satellite offices in Austin, Dallas, Lufkin, Brenham, and Beaumont.

While business couldn't be better, the entrepreneur wants to make sure Houston takes this month to remember the losses and challenges that the LGBT community has endured to get where it is today. Read the full story here.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News